Having trouble accessing articles? Reset your cache.

The count of companies developing vaccines for coronavirus rises

A tally of new vaccines and therapeutics in development for 2019-nCoV

The number of groups that have announced vaccine programs against 2019-nCoV acute respiratory disease has jumped 50% from last week.

As of Feb. 7, 2020, at least 18 companies or academic teams have disclosed that they are developing new vaccines against the virus, up from 12 on Jan. 30 (see "A Dozen Vaccine Programs Underway").

Johnson & Johnson (NYSE:JNJ) remains the only pharma that has announced a vaccine program against 2019-nCoV. Four biotechs and two university groups have thrown their hat in the ring this week (see Table: "Coronavirus Vaccines and Therapies in Development").

The list of new therapeutics in development is rising more slowly, up just one from last week to eight.

Not listed, however, are the numerous antivirals approved for other infections that are now in clinical or preclinical testing for the new virus (see "Clinical Trials for Coronavirus Have Begun").

Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus. The 2019-nCoV content is free to all who visit the site.

Table: Coronavirus vaccines and therapies in development

Listed below are the companies and academic groups that have announced programs to develop new vaccines or therapies for 2019-nCoV acute respiratory disease as of Feb. 7, 2020. Not shown are repurposed agents in clinical or preclinical testing.

 

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE